Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Table of Contents
Primary Topic: biotechnology – Executive Leadership Change & Investment Strategy
Primary Keyword: Zymeworks Investment Officer
Secondary Keywords: Zanidatamab,ziihera,Pasritamig,Biotech Investment,EcoR1 Capital,Kenneth Galbraith,ZYME stock,Biotechnology Leadership,Healthcare Assets
Zymeworks Inc. (ZYME), a Canadian biotechnology company, has appointed Scott Platshon as Acting Chief Investment Officer, effective November 18, 2024. https://www.zymeworks.com/news-releases/ Platshon will report directly too Chair and CEO Kenneth Galbraith and will be responsible for managing cash flows from Zymeworks’ assets, including Ziihera (zanidatamab-hrii), and overseeing the companyS healthcare asset aggregation strategy.
Platshon’s Role and responsibilities
Platshon’s primary focus will be on strategically deploying capital generated from Ziihera and other healthcare assets.This includes licensed product candidates like pasritamig, currently undergoing Phase 3 registration studies with Johnson & Johnson Innovative Medicine.https://www.jnj.com/ He will lead the operational execution of Zymeworks’ strategy to build a portfolio of high-return healthcare investments.
transition from Board Member
With his appointment as Acting CIO, Platshon has resigned from Zymeworks’ Board of directors. He will continue his role as a Partner at EcoR1 Capital, LLC, a venture capital firm specializing in biotechnology investments. https://ecor1capital.com/ This dual role allows Platshon to leverage his investment expertise for both EcoR1 Capital and Zymeworks.
Company and Executive Commentary
Kenneth Galbraith, Chair and CEO of Zymeworks, highlighted the importance of Platshon’s expertise in managing the company’s financial resources and driving long-term value creation. Scott Platshon himself expressed his enthusiasm for continuing to work with Zymeworks in this new capacity, emphasizing the company’s strong financial foundation and the potential to build a disciplined investment portfolio.
“I am eager to continue working closely with Zymeworks, now in this new role, at such a pivotal moment, and share in the Company’s unified strategic vision to pursue innovation and growth. The Company has built a strong financial foundation with Ziihera, its broader platform collaborations and wholly-owned R&D portfolio, and I see tremendous opportunity to leverage these cash flows to build a disciplined, high-return portfolio that creates sustainable value creation over the long-term.” – scott Platshon
Stock Performance
As of November 18, 2024, Zymeworks’ stock (ZYME) experienced volatility. While it closed the previous trading day (Monday, November 17, 2024) at $23.90, up 29.1%, it saw a decline in overnight trading. https://finance.yahoo.com/quote/ZYME/ (Note: stock prices are subject to change).
About Zymeworks
Zymeworks is a Canadian biotechnology company focused on the revelation, development, and commercialization of next-generation antibody-based therapeutics. Their lead product, Ziihera (zanidatamab-hrii), is a bispecific antibody approved for the treatment of certain types of cancer. https://www.zymeworks.com/ The company is also actively pursuing other research and development programs and strategic collaborations to expand its pipeline.